<DOC>
	<DOCNO>NCT01428089</DOCNO>
	<brief_summary>During childhood , level certain hormone : gonadotropin-releasing hormone ( GnRH ) , luteinizing hormone ( LH ) , follicle-stimulating hormone ( FSH ) , estrogen , progesterone low . However , puberty start , GnRH LH pulse begin increase , initially night . It unknown GnRH LH pulse increase night decrease day ( instead increase time ) . The purpose study see quickly progesterone reduces LH pulse . The study also mean find whether much testosterone ( also hormone ) blood cause problem ability progesterone reduce LH pulse . In study , investigator aim discover whether give 3 small dos progesterone pubertal girl prevent nighttime increase LH pulse . From information gather study , investigator may able learn menstrual cycle normally establish girl puberty . Ultimately , investigator understand normal process , investigator may able good understand abnormality puberty .</brief_summary>
	<brief_title>Suppression Daytime Nighttime Luteinizing Hormone Frequency Progesterone</brief_title>
	<detailed_description>Studies perform early pubertal ( late Tanner 1 [ estradiol level &gt; 20 pg/ml ] Tanner 3 , premenarcheal ) girl without hyperandrogenemia ( HA ) . After potential subject identify Pediatric , Teen , Endocrine clinic , come CRU alternate UVA clinical unit outpatient screen exam . The goal procedure study explain potential subject custodial parent , give opportunity ask question . A subject custodial parent ( ) ask sign assent consent form . A physician record family personal medical history perform physical exam . The physical exam include height , weight , determination pubertal stage ( Tanner scale ) . Since adiposity potential confounder study , measure adiposity record . This include measurement waist circumference ( use standard technique ) provide estimate abdominal adiposity . Hip circumference also measure . Additionally , BOD POD® use measure total fat mass , fat free mass , percent body fat . Blood test include CBC , Chem17 , prolactin , LH , FSH , E2 , P , total testosterone , SHBG , DHEA-S , 17-OHP , TSH , insulin , beta-hCG , cytoadipokines . Bone age ( simple x-ray leave hand wrist ) measure . If safety labs abnormal screening ( e.g. , abnormal liver test , abnormal TSH ) , subject ask return repeat ( confirmatory ) labs exclude lab error , especially value slightly abnormal . Repeat test generally occur within one month original screening lab draw . If exclusionary lab value confirm repeat testing , subject exclude participation . If subject low hemoglobin ( &lt; 11.5 g/dL non-African American subject ; Hemoglobin &lt; 11.0 g/dL African American subject ) time screen , offer option take oral iron supplementation dose 1-2 mg/kg 30 day . Subjects weigh ≤ 36 kg give 300-325 mg oral ferrous gluconate daily ( contain 36 mg elemental iron ) ; subject weigh &gt; 36 kg give 300-325 mg oral ferrous gluconate twice daily . Following course iron supplementation , subject return CRU repeat hemoglobin , able proceed study hemoglobin great equal 11.0 g/dL African American subject great equal 11.5 g/dL non-African American subject . If subject 's hemoglobin remain low repeat testing , recommend follow primary physician . If three month elapse admission subject 's recent safety lab , safety lab ( CBC , chemistry liver panel ) obtain prior overnight admission ( admission ) exclude anemia exclusion criterion . Subjects meet inclusion criterion schedule inpatient admission . They begin take iron supplementation maximum 30 day prior admission . Girls weigh ≤ 36 kg take one 300-325 mg tablet oral ferrous gluconate daily ( contain 36 mg elemental iron ) ; subject weigh &gt; 36 kg take two 300-325 tablet oral ferrous gluconate daily ( contain 36 mg elemental iron ) . The inpatient admission occur time period iron supplementation . Inpatient Admission : The subject admit CRU , alternate UVA hospital unit , 0900-1000 h. A urine pregnancy test ( HCG ) obtain . A hemoglobin measured—if CBC do within past 7 day , fingerstick do check hemoglobin prior insertion IV line . Alternatively , subject may come CRU early day admission schedule admission time . The study team responsible scheduling subject . In order continue admission , girl must negative HCG . They must also either hemoglobin ≥ 11.0 g/dL African American subject ≥ 11.5 g/dL non-African American subject . A small amount topical lidocaine prilocaine cream ( EMLA cream ) may apply facilitate IV line placement . An IV line place forearm vein ~1000-1030 h , blood draw begin 1100 h. Samples take every 10 min 20 h ( i.e. , 1100 h 0700 h follow day ) . - Sample volume 0.75 ml every 10 minute later measurement LH . - Every 2 hour ( hour ) , additional 3.5 ml drawn later measurement FSH , T , E2 , P , cortisol . - At 0700 h , additional 3.5 ml draw measurement fast insulin , glucose , SHBG , DHEAS , IGF-1 , androstenedione . Subjects take 5-25 mg oral micronized P ( base body weight , achieve mean plasma P 1-2 ng/ml ) placebo 1100 , 1500 , 1900 h. Formal light occur 2300 h , subject encourage sleep time . Subjects awaken 0700 h. No sleeping allow 1100-2300 h. During blood sampling , activity ( e.g. , awake , sleep ) record nurse every 10 minute . Additionally , period sleep estimate use wrist actigraphy ( Motionlogger Basic-L ; Ambulatory Monitoring , Inc. ) ( 42 ) . The Motionlogger Basic-L watch-like device ( include accelerometer ) wear wrist research participant overnight admission . Subjects fast 2100 0700 h. The subject offer meal standard meal time even prior study , breakfast serve 0700 h sample obtain . Optional Follow-Up study participant : Subjects participate study ask respond questionnaire ( sent via electronic mail US postal service ) and/or phone call 6-12 month interval subsequent three year determine progression normal puberty , onset frequency menses , development hirsutism . Whenever possible , see patient CRU alternate UVA clinical unit time obtain blood hormone analysis include fast insulin glucose , cortisol , SHBG , testosterone , DHEA-S , LH , FSH , estradiol progesterone ( 10 cc blood drawn visit ) ; addition brief physical exam include height , weight , Tanner stage . The follow-up portion study completely optional .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Female volunteer early midpuberty ( i.e. , late Tanner I [ estradiol level &gt; 20 pg/mL ] , Tanner II , Tanner III ) Premenarcheal Pregnancy Inability comprehend do study do Hemoglobin less 12 g/dl hematocrit le 36 % Persistently abnormal sodium , potassium , bicarbonate ( i.e. , confirmed repeat ) Persistently elevate creatinine , hepatic transaminase , alkaline phosphatase ( i.e. , confirmed repeat ) Total bilirubin &gt; 1.5 time upper limit normal ( i.e. , confirmed repeat ) Significant history cardiac pulmonary dysfunction ( e.g. , know suspect congestive heart failure ; asthma require intermittent systemic corticosteroid ; etc . ) Untreated hypo hyperthyroidism , reflect persistently abnormal thyroidstimulating hormone ( TSH ) value Total testosterone &gt; 200 ng/dl Basal ( follicular ) 17hydroxyprogesterone &gt; 200 ng/ml ( girl without previous diagnosis congenital adrenal hyperplasia ) Dehydroepiandrosterone sulfate ( DHEAS ) &gt; 800 mcg/dl Elevation prolactin &gt; 2 time upper limit normal Weight le 26 kg .</criteria>
	<gender>Female</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hyperandrogenemia</keyword>
</DOC>